Dalbavancin
To view the entire topic, please sign in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
- S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)
NON-FDA APPROVED USES
No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
INDICATIONS
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
- S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)
NON-FDA APPROVED USES
No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)
There's more to see -- the rest of this entry is available only to subscribers.